Elephas

Cancer rates are expected to triple by 2060, and despite recent therapeutic advancements, only 1 in 3 patients respond to therapy. Elephas addresses this with its Cybrid platform, which uses advanced imaging, multimodal microscopy, and artificial intelligence to assess live tumor fragments and predict patient treatment response. This unique approach ushers in a new era of diagnostics that accelerates drug development, empowers clinical decision-making, and renews hope for patients around the world.